EVO
Evotec SE · Healthcare
2.60
0.95%(-0.03)
Market OpenLast Updated: — ET
52W L: $2.3152W H: $4.80
$2.60
CHG-0.35 (-12.03%)
H$3.06
L$2.26
VOL2.3M
EVO (1h)
Evotec SE · Healthcare
Evotec said on Tuesday it would continue a dialogue with investor MAK Capital, which has published a list of changes it wants the German biotech firm to make.
Strengthens Supervisory Board leadership to support Evotec's transformation, with a focus on commercial execution, strategic partnerships and profitability Industry veteran brings more than 30 years of global pharmaceutical industry leadership experience across senior management, commercial, operational and strategic roles HAMBURG, DE / ACCESS Newswire / April 7, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that the Supervisory Board of Evotec SE has proposed the election of Dieter Weinand, M.S. as Chairman of the Supervisory Board at the June 11, 2026, Annual General Meeting.
HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) will hold a webcast and conference call to announce its financial results for the fourth quarter and full-year 2025 and provide a business update on Wednesday, April 8, 2026. The conference call will be held in English.
HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer.
Evotec (NASDAQ: EVO - Get Free Report) is anticipated to post its Q4 2025 resultson Wednesday, April 8th. Analysts expect Evotec to post earnings of $0.1126 per share and revenue of $276.9370 million for the quarter. Investors are encouraged to explore the company's upcoming Q4 2025 earning overview page for the latest details on the call
The program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yields Manufacturing process development strengthens U.S. government response capabilities against hemorrhagic fever outbreaks caused by Ebola and Sudan virus HAMBURG, DE / ACCESS Newswire / March 23, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced its Seattle-based subsidiary and CDMO, Just - Evotec Biologics, Inc., has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimization for a monoclonal antibody cocktail targeting filovirus diseases, including Ebola virus (EBOV) and Sudan virus (SUDV). The multi-year program award, valued at up to $10 m if all options are activated, will support BARDA's efforts to strengthen national preparedness by supporting the development of cost‑effective medical countermeasures that can augment the U.S. government's response capabilities with therapeutics targeting filovirus diseases.
Anderson Mark Monroe
director
100,000 SH @ $2.50
2018-10-22
Anderson Mark Monroe
director:
0 SH @ $0.00
2018-10-22
Smith Scott Clifford
director
100,000 SH @ $2.50
2018-08-13
Smith Scott Clifford
director:
0 SH @ $0.00
2018-08-13
LAFFER ARTHUR B
director
100,000 SH @ $2.50
2018-08-13
LAFFER ARTHUR B
director:
0 SH @ $0.00
2018-08-13
QUINTON KEITH
0 SH @ $0.00
2018-10-01
Zientek Michael
officer: Chief Financial Officer
200,000 SH @ $2.50
2018-08-13